Nifty

:

23907.15

Sensex

:

75867.80

-6.55 (-0.03%)
-141.90 (-0.19%)

Login

Nifty
Sensex

:
:

23907.15
75867.80

-6.55 (-0.03%)
-141.90 (-0.19%)

Gland Pharma Ltd.

Pharmaceuticals & Drugs

Rating :

67/99

BSE: 543245 | NSE: GLAND

Watchlist

NSE BSE

2313.00

27-May-2026

Open
High
Low
Previous Close

2324.1
2354.7
2309.2
2307.90

Volume
Traded Value (lacs)
52 Week High
52 Week Low

224401
521487758.2
2396
1513.4

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

38,113.10
37.10
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

34,935.46
0.86%
3.68

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.81
10.16
15.72

EBITDA CAGR (%)

10 Years
5 Years
3 Years

11.13
-0.52
4.37

PAT CAGR (%)

10 Years
5 Years
3 Years

13.26
-6.87
-3.65

P:E (Median)

8 Years
5 Years
3 Years

-
38.36
38.80

P:BV (Average)

8 Years
5 Years
3 Years

-
4.31
3.21

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
20.85
17.91

Earnings Forecasts:

(Updated: 23-05-2026)

Description 2024 2025 2026 2027
Adj EPS 56.55 72.99 88.9 107.51
P/E Ratio 40.90 31.69 26.02 21.51
Revenue 6355.4 7299.37 8269.73 9486.14
EBITDA 1538.11 1890.65 2226.93 2662.23
Net Income 932.49 1201.89 1466.79 1771.9
ROA 8.51 9.77 11.1 11.3
P/B Ratio 3.88 3.42 3.09 2.85
ROE 9.88 11.16 12.21 13.73
FCFF 533.23 426.64 828.9 1000.32
FCFF Yield 1.59 1.27 2.47 2.98
Net Debt -2585.17 -3306.19 -4239.22 -5349.07
BVPS 596.4 677.1 748.21 810.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 1,261.59 1,030.35 22.44% 1,177.51 1,010.78 16.50% 1,074.15 1,062.99 1.05% 1,038.84 1,012.02 2.65%
Expenses 753.88 636.23 18.49% 755.89 619.64 21.99% 699.26 699.19 0.01% 679.99 718.47 -5.36%
EBITDA 507.72 394.12 28.82% 421.63 391.14 7.80% 374.89 363.80 3.05% 358.85 293.55 22.24%
EBIDTM 40.24% 38.25% 35.81% 38.70% 34.90% 34.22% 34.54% 29.01%
Other Income 106.36 43.72 143.28% 60.21 65.06 -7.45% 82.59 57.80 42.89% 54.74 48.49 12.89%
Interest 6.17 3.45 78.84% 0.50 18.31 -97.27% 3.97 0.17 2,235.29% 7.43 0.91 716.48%
Depreciation 43.11 43.07 0.09% 44.53 43.77 1.74% 44.84 41.61 7.76% 43.77 40.82 7.23%
PBT 564.80 391.32 44.33% 412.46 394.13 4.65% 408.67 379.82 7.60% 362.38 300.31 20.67%
Tax 144.35 101.32 42.47% 104.61 99.01 5.66% 106.68 98.11 8.74% 93.13 77.39 20.34%
PAT 420.45 290.00 44.98% 307.85 295.12 4.31% 302.00 281.71 7.20% 269.26 222.92 20.79%
PATM 33.33% 28.15% 26.14% 29.20% 28.11% 26.50% 25.92% 22.03%
EPS 25.51 17.60 44.94% 18.68 17.91 4.30% 18.32 17.09 7.20% 16.34 13.53 20.77%

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 1,742.79 1,424.91 22.31% 1,695.36 1,384.05 22.49% 1,486.88 1,405.83 5.77% 1,505.62 1,401.71 7.41%
Expenses 1,229.77 1,077.39 14.14% 1,260.49 1,024.10 23.08% 1,172.99 1,108.78 5.79% 1,137.86 1,137.31 0.05%
EBITDA 513.02 347.52 47.62% 434.88 359.96 20.81% 313.89 297.06 5.67% 367.76 264.40 39.09%
EBIDTM 29.44% 24.39% 25.65% 26.01% 21.11% 21.13% 24.43% 18.86%
Other Income 111.47 44.03 153.17% 63.17 58.49 8.00% 84.16 59.66 41.07% 57.53 51.43 11.86%
Interest 10.03 7.45 34.63% 3.93 22.82 -82.78% 7.82 6.11 27.99% 11.50 5.62 104.63%
Depreciation 108.66 95.76 13.47% 107.65 96.33 11.75% 106.31 93.83 13.30% 101.05 91.96 9.88%
PBT 505.80 288.33 75.42% 362.13 299.30 20.99% 283.92 256.78 10.57% 312.74 218.24 43.30%
Tax 139.12 101.79 36.67% 100.65 94.61 6.38% 100.23 93.25 7.49% 97.26 74.48 30.59%
PAT 366.68 186.54 96.57% 261.48 204.69 27.74% 183.68 163.53 12.32% 215.48 143.76 49.89%
PATM 21.04% 13.09% 15.42% 14.79% 12.35% 11.63% 14.31% 10.26%
EPS 22.26 11.32 96.64% 15.87 12.42 27.78% 11.15 9.93 12.29% 13.08 8.73 49.83%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 4,552.09 4,116.15 4,167.43 3,616.53 4,400.71 3,462.88 2,633.24 2,044.20 1,619.94 1,479.18 1,347.87 Net Sales Growth 10.59% -1.23% 15.23% -17.82% 27.08% 31.51% 28.82% 26.19% 9.52% 9.74% Cost Of Goods Sold 1,795.16 1,730.60 1,820.31 1,685.42 2,109.22 1,219.00 836.07 626.35 479.75 375.07 540.21 Gross Profit 2,756.93 2,385.55 2,347.12 1,931.10 2,291.49 2,243.88 1,797.18 1,417.85 1,140.18 1,104.11 807.66 GP Margin 60.56% 57.96% 56.32% 53.40% 52.07% 64.80% 68.25% 69.36% 70.38% 74.64% 59.92% Total Expenditure 2,889.02 2,673.53 2,758.65 2,597.98 2,890.07 2,160.61 1,677.77 1,337.89 1,084.84 854.19 845.63 Power & Fuel Cost - 120.38 117.19 124.84 95.05 74.58 78.50 74.03 60.35 49.24 46.96 % Of Sales - 2.92% 2.81% 3.45% 2.16% 2.15% 2.98% 3.62% 3.73% 3.33% 3.48% Employee Cost - 439.02 409.94 399.70 338.57 311.36 277.66 222.95 179.08 153.42 131.30 % Of Sales - 10.67% 9.84% 11.05% 7.69% 8.99% 10.54% 10.91% 11.05% 10.37% 9.74% Manufacturing Exp. - 222.18 218.95 194.21 179.85 436.84 391.88 337.81 269.23 217.13 72.95 % Of Sales - 5.40% 5.25% 5.37% 4.09% 12.61% 14.88% 16.53% 16.62% 14.68% 5.41% General & Admin Exp. - 98.95 109.27 119.02 93.79 58.62 57.77 47.00 78.76 42.74 32.91 % Of Sales - 2.40% 2.62% 3.29% 2.13% 1.69% 2.19% 2.30% 4.86% 2.89% 2.44% Selling & Distn. Exp. - 23.31 34.66 30.26 40.98 36.69 17.08 13.88 9.93 11.40 15.80 % Of Sales - 0.57% 0.83% 0.84% 0.93% 1.06% 0.65% 0.68% 0.61% 0.77% 1.17% Miscellaneous Exp. - 39.10 48.31 44.53 32.61 23.51 18.82 15.86 7.73 5.19 15.80 % Of Sales - 0.95% 1.16% 1.23% 0.74% 0.68% 0.71% 0.78% 0.48% 0.35% 0.41% EBITDA 1,663.09 1,442.62 1,408.78 1,018.55 1,510.64 1,302.27 955.47 706.31 535.10 624.99 502.24 EBITDA Margin 36.53% 35.05% 33.80% 28.16% 34.33% 37.61% 36.28% 34.55% 33.03% 42.25% 37.26% Other Income 303.90 215.07 166.67 240.46 223.94 134.78 139.17 85.56 48.79 33.56 36.76 Interest 18.07 22.84 7.84 7.41 5.24 3.41 7.18 3.56 4.13 6.39 16.42 Depreciation 176.25 169.27 162.11 146.74 110.30 98.78 94.59 81.96 78.21 74.15 63.46 PBT 1,748.31 1,465.59 1,405.50 1,104.86 1,619.04 1,334.85 992.87 706.36 501.56 578.01 459.11 Tax 448.77 375.83 362.17 272.58 406.89 337.85 220.01 234.45 180.45 164.28 145.51 Tax Rate 25.67% 25.64% 25.77% 26.00% 25.13% 25.31% 22.16% 34.16% 35.98% 28.42% 31.69% PAT 1,299.56 1,089.75 1,043.33 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 PAT before Minority Interest 1,299.56 1,089.75 1,043.33 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 28.55% 26.47% 25.04% 21.45% 27.54% 28.79% 29.35% 22.11% 19.82% 27.97% 23.27% PAT Growth 19.25% 4.45% 34.48% -36.00% 21.58% 29.00% 71.02% 40.73% -22.39% 31.93% EPS 78.86 66.13 63.31 47.08 73.55 60.50 46.90 27.42 19.48 25.10 19.03

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Net Sales 6,430.65 5,616.50 5,664.72 3,624.60 4,400.71 3,462.88 2,633.24 Net Sales Growth 14.50% -0.85% 56.29% -17.64% 27.08% 31.51% Cost Of Goods Sold 2,242.93 2,090.38 2,173.09 1,685.42 2,109.22 1,219.00 836.07 Gross Profit 4,187.72 3,526.12 3,491.63 1,939.17 2,291.49 2,243.88 1,797.18 GP Margin 65.12% 62.78% 61.64% 53.50% 52.07% 64.80% 68.25% Total Expenditure 4,801.11 4,347.58 4,331.65 2,599.84 2,890.56 2,160.65 1,677.77 Power & Fuel Cost - 199.15 229.99 124.84 95.05 74.58 78.50 % Of Sales - 3.55% 4.06% 3.44% 2.16% 2.15% 2.98% Employee Cost - 1,401.56 1,256.89 403.26 338.57 311.36 277.66 % Of Sales - 24.95% 22.19% 11.13% 7.69% 8.99% 10.54% Manufacturing Exp. - 347.18 327.19 194.23 179.85 436.84 391.88 % Of Sales - 6.18% 5.78% 5.36% 4.09% 12.61% 14.88% General & Admin Exp. - 206.62 217.36 120.53 94.28 58.66 57.77 % Of Sales - 3.68% 3.84% 3.33% 2.14% 1.69% 2.19% Selling & Distn. Exp. - 27.48 37.46 27.03 40.98 36.69 17.08 % Of Sales - 0.49% 0.66% 0.75% 0.93% 1.06% 0.65% Miscellaneous Exp. - 75.20 89.66 44.53 32.61 23.51 18.82 % Of Sales - 1.34% 1.58% 1.23% 0.74% 0.68% 0.71% EBITDA 1,629.55 1,268.92 1,333.07 1,024.76 1,510.15 1,302.23 955.47 EBITDA Margin 25.34% 22.59% 23.53% 28.27% 34.32% 37.61% 36.28% Other Income 316.33 213.61 170.24 240.46 223.94 134.78 139.17 Interest 33.28 42.00 26.20 7.45 5.24 3.41 7.18 Depreciation 423.67 377.87 344.57 146.74 110.30 98.78 94.59 PBT 1,464.59 1,062.66 1,132.54 1,111.04 1,618.55 1,334.81 992.87 Tax 437.26 364.13 360.08 273.54 406.89 337.85 220.01 Tax Rate 29.86% 34.27% 31.79% 25.94% 25.14% 25.31% 22.16% PAT 1,027.32 698.53 772.46 781.04 1,211.66 996.96 772.86 PAT before Minority Interest 1,027.32 698.53 772.46 781.04 1,211.66 996.96 772.86 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 15.98% 12.44% 13.64% 21.55% 27.53% 28.79% 29.35% PAT Growth 47.07% -9.57% -1.10% -35.54% 21.54% 29.00% EPS 62.34 42.39 46.87 47.39 73.52 60.50 46.90

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 9,755.10 8,995.29 7,953.30 7,158.23 5,903.28 3,646.24 2,862.11 2,410.42 2,089.81 1,677.07 Share Capital 16.48 16.47 16.47 16.43 16.36 15.49 15.49 15.49 15.49 15.49 Total Reserves 9,738.57 8,977.43 7,935.16 7,128.56 5,861.51 3,614.26 2,846.62 2,394.93 2,074.32 1,661.57 Non-Current Liabilities 142.75 131.60 89.68 93.97 80.31 80.78 127.79 139.37 130.55 121.95 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.17 Unsecured Loans 1.11 2.55 3.26 3.82 3.93 4.07 4.96 5.49 5.92 6.37 Long Term Provisions 22.84 20.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Liabilities 523.76 414.20 730.20 581.94 512.46 359.02 532.68 378.55 253.38 287.29 Trade Payables 385.87 281.19 589.42 462.76 396.28 249.09 446.20 292.42 189.29 88.51 Other Current Liabilities 88.03 100.94 109.46 76.42 62.36 81.73 72.60 71.13 61.87 151.77 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.90 Short Term Provisions 49.87 32.07 31.32 42.75 53.82 28.20 13.88 15.01 2.23 7.12 Total Liabilities 10,421.61 9,541.09 8,773.18 7,834.14 6,496.05 4,086.04 3,522.58 2,928.34 2,473.74 2,086.31 Net Block 1,744.99 1,693.73 1,570.55 1,502.19 954.23 968.10 928.74 842.64 871.58 787.88 Gross Block 2,798.04 2,579.91 2,294.95 2,081.32 1,430.70 1,347.81 1,219.58 1,054.45 1,005.52 1,020.22 Accumulated Depreciation 1,053.05 886.18 724.41 579.13 476.46 379.71 290.83 211.81 133.94 232.34 Non Current Assets 4,654.65 4,969.76 1,884.84 1,989.70 1,372.99 1,239.75 1,165.13 1,077.36 1,065.60 1,014.41 Capital Work in Progress 42.20 120.00 177.22 190.75 337.81 188.47 123.16 198.88 161.15 202.10 Non Current Investment 2,789.57 2,385.74 8.16 8.16 0.55 0.00 0.00 0.00 0.00 0.17 Long Term Loans & Adv. 77.89 114.38 128.92 286.40 77.97 81.52 111.89 33.89 29.42 21.63 Other Non Current Assets 0.00 655.91 0.00 2.21 2.43 1.66 1.33 1.95 3.44 2.62 Current Assets 5,766.96 4,571.32 6,888.34 5,844.44 5,123.07 2,846.29 2,357.46 1,850.98 1,408.15 1,071.90 Current Investments 0.00 0.00 0.00 154.87 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,254.23 1,260.21 1,945.30 1,185.67 1,275.17 756.28 911.88 512.83 378.72 367.08 Sundry Debtors 1,142.90 1,171.40 862.84 1,074.81 670.97 601.78 506.10 475.21 417.87 350.69 Cash & Bank 2,432.62 1,598.55 3,767.00 3,085.80 3,005.20 1,325.19 753.35 670.84 533.08 273.23 Other Current Assets 937.21 104.76 90.83 96.75 171.72 163.03 186.13 192.10 78.48 80.91 Short Term Loans & Adv. 810.85 436.41 222.37 246.55 87.60 91.80 131.94 126.45 30.20 36.37 Net Current Assets 5,243.20 4,157.13 6,158.14 5,262.50 4,610.61 2,487.27 1,824.78 1,472.43 1,154.77 784.61 Total Assets 10,421.61 9,541.08 8,773.18 7,834.14 6,496.06 4,086.04 3,522.59 2,928.34 2,473.75 2,086.31

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Shareholder's Funds 9,150.74 8,723.84 7,958.72 7,157.62 5,903.24 3,646.24 Share Capital 16.48 16.47 16.47 16.43 16.36 15.49 Total Reserves 9,134.21 8,705.99 7,940.59 7,127.95 5,861.46 3,614.26 Non-Current Liabilities 457.27 488.60 89.68 93.97 80.31 80.78 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 77.66 106.54 3.26 3.82 3.93 4.07 Long Term Provisions 145.99 137.21 0.00 0.00 0.00 0.00 Current Liabilities 1,564.85 1,398.36 729.13 582.02 512.53 359.02 Trade Payables 820.41 767.75 587.35 462.85 396.35 249.09 Other Current Liabilities 619.87 520.07 109.48 76.42 62.36 81.73 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 124.56 110.54 32.30 42.75 53.82 28.20 Total Liabilities 11,172.86 10,610.80 8,777.53 7,833.61 6,496.08 4,086.04 Net Block 4,147.23 3,946.75 1,570.55 1,502.19 954.23 968.10 Gross Block 5,613.37 5,011.68 2,294.95 2,081.32 1,430.70 1,347.81 Accumulated Depreciation 1,466.14 1,064.93 724.41 579.13 476.46 379.71 Non Current Assets 4,389.91 4,965.66 1,876.73 1,981.54 1,372.44 1,239.75 Capital Work in Progress 150.56 237.88 177.22 190.75 337.81 188.47 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 87.69 119.43 128.96 286.40 77.97 81.52 Other Non Current Assets 4.43 661.59 0.00 2.21 2.43 1.66 Current Assets 6,782.94 5,645.15 6,900.81 5,852.08 5,123.64 2,846.29 Current Investments 0.00 0.00 0.00 154.87 0.00 0.00 Inventories 1,685.22 1,655.24 1,945.30 1,185.67 1,275.17 756.28 Sundry Debtors 1,516.53 1,558.69 871.39 1,074.81 670.97 601.78 Cash & Bank 2,556.21 1,839.43 3,770.68 3,093.44 3,005.75 1,325.19 Other Current Assets 1,024.98 102.61 91.00 96.75 171.75 163.03 Short Term Loans & Adv. 875.13 489.19 222.44 246.55 87.60 91.80 Net Current Assets 5,218.09 4,246.79 6,171.68 5,270.05 4,611.11 2,487.27 Total Assets 11,172.85 10,610.81 8,777.54 7,833.62 6,496.08 4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,073.67 1,135.97 367.89 791.29 604.93 700.93 185.06 201.93 476.46 224.09 PBT 1,465.59 1,405.50 1,048.40 1,619.04 1,334.85 992.87 686.36 501.56 578.01 459.11 Adjustment -5.15 23.15 37.38 -28.19 17.30 32.15 76.12 50.94 70.69 68.72 Changes in Working Capital -34.59 23.38 -407.00 -393.05 -435.80 -79.94 -353.94 -193.43 -10.86 -187.17 Cash after chg. in Working capital 1,425.84 1,452.02 678.78 1,197.80 916.36 945.07 408.53 359.07 637.85 340.66 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -352.17 -316.05 -310.89 -406.51 -311.43 -244.14 -223.47 -157.14 -161.39 -116.56 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,578.20 -2,923.92 1,208.22 -1,010.23 -1,524.55 -766.08 -314.14 -358.84 -96.65 -11.91 Net Fixed Assets -140.33 -227.74 -200.10 -503.56 -232.23 -193.54 -89.41 -86.66 55.65 -209.75 Net Investments -403.83 -2,377.58 154.87 -162.48 -0.55 0.00 0.00 0.00 0.17 0.00 Others 2,122.36 -318.60 1,253.45 -344.19 -1,291.77 -572.54 -224.73 -272.18 -152.47 197.84 Cash from Financing Activity -339.54 -7.40 14.92 34.90 1,238.46 -6.87 -2.93 -3.59 -116.42 -92.90 Net Cash Inflow / Outflow 2,312.33 -1,795.35 1,591.04 -184.04 318.84 -72.01 -132.01 -160.50 263.39 119.29 Opening Cash & Equivalents 116.20 1,905.22 311.18 491.92 169.50 236.40 372.84 533.08 273.23 157.81 Closing Cash & Equivalent 2,432.62 116.20 1,905.22 311.18 491.92 169.50 236.40 372.84 533.08 273.23

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Cash From Operating Activity 914.73 996.80 363.97 790.77 604.93 700.93 PBT 1,062.66 1,132.54 1,054.58 1,618.55 1,334.81 992.87 Adjustment 211.94 223.60 38.19 -28.27 17.30 32.15 Changes in Working Capital -6.06 -53.20 -417.94 -393.01 -435.76 -79.94 Cash after chg. in Working capital 1,268.53 1,302.95 674.83 1,197.28 916.35 945.07 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -353.80 -306.15 -310.87 -406.51 -311.43 -244.14 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,704.74 -1,756.91 1,208.19 -1,002.62 -1,524.00 -766.08 Net Fixed Assets -140.33 -227.74 -200.10 -503.56 -232.23 Net Investments -403.83 -2,377.58 154.87 -162.48 -0.55 Others 2,248.90 848.41 1,253.42 -336.58 -1,291.22 Cash from Financing Activity -433.48 -799.42 14.92 34.90 1,238.46 -6.87 Net Cash Inflow / Outflow 2,185.99 -1,559.53 1,587.08 -176.95 319.39 -72.01 Opening Cash & Equivalents 357.09 1,908.89 318.82 492.46 169.50 236.40 Closing Cash & Equivalent 2,556.21 357.09 1,908.89 318.82 492.46 169.50

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 592.08 546.04 482.80 434.87 359.30 234.25 1847.12 1555.61 1348.70 1082.33 ROA 10.92% 11.39% 9.34% 16.92% 18.84% 20.32% 14.01% 11.89% 18.15% 16.31% ROE 11.62% 12.31% 10.28% 18.62% 20.97% 23.81% 17.14% 14.27% 21.97% 20.42% ROCE 15.87% 16.67% 13.97% 24.86% 28.00% 30.68% 26.11% 22.41% 30.04% 28.35% Fixed Asset Turnover 1.53 1.71 1.65 2.51 2.49 2.05 1.80 1.58 1.47 1.47 Receivable days 102.61 89.08 97.78 72.40 67.08 76.78 87.61 100.43 94.03 69.91 Inventory Days 111.48 140.38 158.00 102.05 107.06 115.61 127.19 100.26 91.25 92.53 Payable days 70.34 87.28 113.93 74.33 96.62 73.57 99.56 79.68 57.64 32.44 Cash Conversion Cycle 143.75 142.17 141.84 100.12 77.52 118.83 115.24 121.01 127.64 129.99 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 Interest Cover 65.18 180.20 142.41 309.98 392.34 139.24 193.80 122.59 91.43 28.97

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Book Value (Rs.) 555.40 529.56 483.12 434.84 359.30 234.25 ROA 6.41% 7.97% 9.40% 16.91% 18.84% 18.91% ROE 7.82% 9.26% 10.34% 18.61% 20.97% 21.29% ROCE 11.97% 13.63% 14.04% 24.85% 28.00% 27.39% Fixed Asset Turnover 1.06 1.55 1.66 2.51 2.49 1.95 Receivable days 99.92 78.29 97.99 72.40 67.08 83.41 Inventory Days 108.54 116.00 157.65 102.05 107.06 104.83 Payable days 138.65 113.80 113.72 74.35 96.63 52.71 Cash Conversion Cycle 69.81 80.48 141.92 100.10 77.51 135.53 Total Debt/Equity 0.03 0.04 0.00 0.00 0.00 0.00 Interest Cover 26.30 44.23 142.61 309.77 392.33 139.24

Top Investors:

mirae asset large & midcap fund

hdfc mutual fund - hdfc mid-cap fund

nippon life india trustee ltd- a/c nippon india growth mid cap fund

sbi large & midcap fund

icici prudential india opportunities fund

dsp small cap fund

government pension fund global

uti-flexi cap fund

Annual Reports:

News Update:

Gland Pharma’s consolidated net profit jumps 97% in Q4
18th May 2026, 14:21 PM

The total consolidated income of the company increased by 26.23% at Rs 1,854.26 crore for Q4FY26
Read More
Gland Pharma - Quarterly Results
16th May 2026, 00:00 AM

Read More
Gland Pharma gets USFDA’s tentative nod for Brimonidine Tartrate Ophthalmic Solution
4th Mar 2026, 12:26 PM

The product is indicated to relieve redness of the eye
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback